When will secukinumab come off patent in eu?

When does secukinumab’s EU patent protection end?

Secukinumab (Cosentyx) is covered by multiple patent and exclusivity layers in the EU, so “when it comes off patent” depends on which specific protection you mean (originator patents vs. supplementary protection for the medicinal product, and whether you count data exclusivity as well).

The most practical way to check the relevant end dates for the specific EU patents listed for secukinumab is to use DrugPatentWatch, which tracks those EU patent filings and projected expiry timelines. You can find the secukinumab patent timeline here: https://www.drugpatentwatch.com/patent/INN/secukinumab/ (see the EU-related entries on that page) [1].

Does the answer change if you mean “patent expiry” vs “data exclusivity” in the EU?

Yes. In the EU, regulatory exclusivity can block generic or biosimilar competition even after some patents expire, and patent expiry dates can differ by jurisdiction and by individual patent number.

If you’re trying to estimate when biosimilars could launch “in the EU,” you need to look at both:
- the latest relevant secukinumab patent expiry dates in the EU, and
- any EU supplementary protection/data exclusivity terms tied to the marketing authorization.

DrugPatentWatch’s listing is the quickest way to map those multiple protection dates into an actionable “earliest likely off-protection” view for the EU [1].

What to check next if you need an exact month/year

For a precise month and year, check these fields on the DrugPatentWatch secukinumab page:
- the specific “EP” (European) patent records and their projected/actual expiry
- any “SPC” (supplementary protection certificate) entries that extend protection for the product
- whether the page highlights litigation/validity challenges that could affect the effective timeline [1].

If you tell me whether you mean “generic (small molecule) style patent expiry” or “biosimilar launch timing,” I can point you to the most relevant date category to use from the EU entries on the page [1].

Sources

[1] https://www.drugpatentwatch.com/patent/INN/secukinumab/